Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Program topic
No spam. Unsubscribe anytime.
CCA staff outline Virginia medical cannabis rules, testing and sales data
Summary
A Cannabis Control Authority official reviewed the medical cannabis program's product registration, testing, seed-to-sale tracking and recent sales figures, and said prescriber certification via telehealth remains permitted.
A Cannabis Control Authority official told the Cannabis Public Health Advisory Council that Virginia's medical cannabis program is organized by five health service areas with limits on vertically integrated facilities and rigorous product registration and testing requirements. The official said the state implemented a seed-to-sale tracking system last summer that can stop product dispensation if a batch fails compliance testing.
"We have direct access and eyes on any medical cannabis in the Commonwealth while it is in any stage of production," the CCA official said, and noted that the system records transfers to labs and flags noncompliant batches. The official cited about $75,000,000 in medical cannabis sales from January through the end of May and said the program has averaged roughly $15,000,000 per month since tracking began.
Members pressed for patient and prescriber data. The CCA official said unique patients dispensed cannabis in May numbered about 53,000 and that calendar-year figures were roughly 114,000 for 2025 (up from 104,000 in 2024). On prescribers, the official said registration of practitioners was removed several years ago and that doctors, nurse practitioners and physician assistants may certify patients; telehealth is permitted for certification.
Why it matters: The presentation describes the current regulatory baseline the council will use as Virginia moves toward an adult-use market and highlights where existing medical safeguards (testing, pharmacist oversight and tracking) could be applied to future retail regulations.
